Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05449106
Other study ID # KY2022-054-02
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 25, 2022
Est. completion date May 25, 2032

Study information

Verified date August 2023
Source Beijing Tiantan Hospital
Contact Shaosen Zhang, Doctor
Phone +8618611284839
Email longyoubafang@hotmail.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The purpose of this study is to investigate the role of multimodal CT in evaluating and predicting different clinical outcomes in patients with unruptured brain arteriovenous malformations with medical management alone. This study will be undertaken in the following aspects: 1. Morphological, structural and imaging histological signal analysis based on multimodal CT to explore the relationship between imaging features and different clinical outcomes of bAVMs. 2. Hemodynamic and flow pattern analysis of local and peripheral bAVMs based on multimodal CT to explore the association between blood flow features and different clinical outcomes. 3. Based on multimodal CT and deep learning algorithms to create an automated segmentation model for bAVMs and a prediction model for distinct clinical outcomes. The obtained patient information includes: Baseline information, CT, MRI, DSA (Optional), and follow-up information. Follow-up will be undertaken at 6 months, 12 months, 24 months and 36 months after enrollment with the following primary observation. Main observation endpoints: 1. Hemorrhage events associated with bAVMs 2. New epilepsy symptoms or exacerbations 3. New neurological dysfunction(including motor dysfunction, cognitive dysfunction, etc).


Description:

This study is a Long-term, multi-center, prospective registry study, and was supported by China National Key Research and Development Program Project No. 2021YFC2500502. The purpose of this study is to investigate the role of multimodal Computer Tomography(CT) in evaluating and predicting different clinical outcomes in patients with unruptured brain arteriovenous malformations with medical management alone. This study will be undertaken in the following aspects: 1. Morphological, structural and imaging histological signal analysis based on multimodal CT to study the relationship between imaging features and different clinical outcomes of bAVMs. 2. Hemodynamic and flow pattern analysis of local and peripheral bAVMs based on multimodal CT to explore the association between blood flow features and different clinical outcomes. 3. Based on multimodal CT and deep learning algorithms to create an automated segmentation model for bAVMs and a prediction model for distinct clinical outcomes. 4. To compare the efficacy of multimodal CT and MRI in evaluating the clinical outcomes of unruptured cerebral arteriovenous malformations. The obtained patient information includes: 1. Baseline information 2. CT images: including non-contrast CT(NCCT), CT Angiography, CT perfusion 3. Magnetic Resonance Imaging(MRI): including T1-weighted image, T2-weighted image, T2-FLAIR, Time of Flight MR angiography(TOF-MRA), diffusion-weighted imaging(DWI), susceptibility weighted imaging(SWI) 4. Digital subtraction angiography(DSA, optional) 5. Follow-up information: follow-up will be undertaken at 6 months, 12 months, 24 months and 36 months after enrollment with the following primary observation. Main observation endpoints: 1. Hemorrhage events associated with bAVMs, ensuring by CT scan; 2. New epilepsy symptoms or exacerbations, ensuring by consultation or EEG ; 3. New neurological dysfunction(including motor dysfunction, cognitive dysfunction, etc), ensuring by consultation, physical examination or any radiology examination. Inclusion criteria 1. Patients with confirmed diagnosis of bAVMs in the cerebrum, basal ganglia, thalamus, corpus callosum, cerebellum and brainstem; 2. Patients with no history of previous bAVM related hemorrhage confirmed by CT examination, or have radiographic examination completed prior to the hemorrhage. 3. Patients with radiographic examinations before any treatment; Exclusion criteria. 1. Patients with simple arteriovenous fistula; 2. Patients with combined dural arteriovenous fistula; 3. Arteriovenous malformations occurring in the spinal cord; 4. Pregnant patients were not included in this study.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date May 25, 2032
Est. primary completion date May 25, 2027
Accepts healthy volunteers No
Gender All
Age group 3 Years to 80 Years
Eligibility Inclusion Criteria: 1. Patients with confirmed diagnosis of brain arteriovenous malformations in the brain, basal ganglia, thalamus, corpus callosum, cerebellum and other locations. 2. Patients with no history of previous arteriovenous malformation-related hemorrhage and no arteriovenous malformation-related hemorrhage confirmed by CT examination. 3. Patients with Radiographic examinations completed without any treatment Exclusion Criteria: 1. Patients with simple arteriovenous fistula. 2. Patients with combined dural arteriovenous fistulas. 3. Arteriovenous malformations occurring in the spinal cord. 4. Pregnant patients were not included in this study.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Beijing Hospital Beijing Beijing
China Beijing Tiantan Hospital, Capital Medical University Beijing Beijing
China The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Nanjing Jiangsu
China The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan

Sponsors (4)

Lead Sponsor Collaborator
Beijing Tiantan Hospital Beijing Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital of Zhengzhou University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with rupture events Arteriovenous malformation rupture during follow-up before treatment 3 years after enrollment
Primary Number of participants with epilepsy Progression Progression of seizure symptoms during follow-up, including but not limited to more frequent seizures, worsening of symptoms, etc. 3 years after enrollment
Primary Number of participants with new onset neurological dysfunction New neurological deficits during the follow-up period, including motor deficits, cognitive deficits, etc. 3 years after enrollment
Secondary Number of participants receiving treatment Patients receiving any form of intervention during the follow-up period will stop the follow-up 3 years after enrollment
See also
  Status Clinical Trial Phase
Completed NCT00857662 - Study Comparing Onyx and TRUFILL in Brain Arteriovenous Malformations (AVMs) Phase 2
Recruiting NCT02896881 - Interest of New MRI Sequences After Embolization of Brain Arteriovenous Malformations